Genica Pharmaceuticals becomes Athena Diagnostics:
This article was originally published in Clinica
Following completion of the acquisition of Genica Pharmaceuticals by Athena Neurosciences (see Clinica No 635, p 13), Genica is to be renamed Athena Diagnostics. Operating as a wholly-owned subsidiary of Athena, it will retain its headquarters in Massachusetts. Transaction costs associated with the merger are not expected to exceed $1.75 million.